Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RPRX Stock Forecast 2026-2027
$45.65
Current Price
$26.40B
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RPRX Price Targets
+33.6%
To High Target of $61.00
+11.7%
To Median Target of $51.00
+0.8%
To Low Target of $46.00
RPRX Price Momentum
+0.5%
1 Week Change
+1.0%
1 Month Change
+39.3%
1 Year Change
+18.1%
Year-to-Date Change
-4.6%
From 52W High of $47.86
+53.9%
From 52W Low of $29.66
📊 TOP ANALYST CALLS
Did RPRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Royalty Pharma is one of their latest high-conviction picks.
Latest RPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, RPRX has a bullish consensus with a median price target of $51.00 (ranging from $46.00 to $61.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $45.65, the median forecast implies a 11.7% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Harrison at Morgan Stanley, suggesting a 0.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPRX Analyst Ratings
8
Buy
2
Hold
0
Sell
RPRX Price Target Range
Low
$46.00
Average
$51.00
High
$61.00
Current: $45.65
Latest RPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 27, 2026 | Citigroup | Geoff Meacham | Buy | Maintains | $50.00 |
| Dec 11, 2025 | TD Cowen | Steve Scala | Buy | Maintains | $45.00 |
| Oct 10, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Sep 30, 2025 | Goldman Sachs | Asad Haider | Buy | Initiates | $42.00 |
| Jul 22, 2025 | Citigroup | Geoff Meacham | Buy | Maintains | $42.00 |
| Jul 10, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Oct 25, 2024 | Citigroup | Andrew Baum | Buy | Maintains | $40.00 |
| Aug 14, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $51.00 |
| Jul 11, 2024 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $51.00 |
| Jun 3, 2024 | UBS | Ashwani Verma | Neutral | Downgrade | $28.00 |
| Apr 12, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $38.00 |
| Feb 20, 2024 | JP Morgan | Chris Schott | Overweight | Maintains | $42.00 |
| Feb 20, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $50.00 |
| Nov 9, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $57.00 |
| Oct 11, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Aug 9, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $53.00 |
| Jul 11, 2023 | Morgan Stanley | Terence Flynn | Overweight | Reiterates | $52.00 |
| May 10, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $52.00 |
| Apr 10, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $50.00 |
| Apr 10, 2023 | Tigress Financial | Buy | Reiterates | $N/A |
Royalty Pharma plc (RPRX) Competitors
The following stocks are similar to Royalty Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RPRX
Royalty Pharma
mkt cap
26.40B
Royalty Pharma plc (RPRX) Financial Data
Royalty Pharma plc has a market capitalization of $26.40B with a P/E ratio of 25.8x. The company generates $2.38B in trailing twelve-month revenue with a 32.4% profit margin.
Revenue growth is +4.8% quarter-over-quarter, while maintaining an operating margin of +57.7% and return on equity of +13.2%.
Valuation Metrics
Market Cap
$26.40B
Enterprise Value
$31.57B
P/E Ratio
25.8x
PEG Ratio
8.4x
Price/Sales
11.2x
Growth & Margins
Revenue Growth (YoY)
+4.8%
Gross Margin
N/A
Operating Margin
+57.7%
Net Margin
+32.4%
EPS Growth
+2.9%
Financial Health
Cash/Price Ratio
+3.3%
Current Ratio
2.4x
Debt/Equity
92.3x
ROE
+13.2%
ROA
+5.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Royalty Pharma plc (RPRX) Business Model
About Royalty Pharma plc
What They Do
Acquires biopharmaceutical royalties and funds innovation.
Business Model
The company makes money by acquiring royalties that provide it with a share of the sales from approved therapies and developmental products. By partnering with various innovators across the life sciences sector, it generates revenue through these royalty payments, while also offering non-dilutive funding solutions to support clinical trials and product launches.
Additional Information
Royalty Pharma holds a diverse portfolio with royalties on over 35 commercial products for various medical conditions, as well as more than 20 pipeline assets. Founded in 1996 and headquartered in New York, it has established itself as a leader in biopharma royalty transactions, contributing to advancements in healthcare and bio-innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Mr. Pablo Legorreta
Country
United States
IPO Year
2020
Website
www.royaltypharma.comRoyalty Pharma plc (RPRX) Latest News & Analysis
Latest News
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12 days ago
Quick Summary
Royalty Pharma plc (RPRX) presented at the TD Cowen 46th Annual Health Care Conference, discussing key developments and strategies.
Why It Matters
Royalty Pharma's presentation could signal strategic developments or financial performance insights, influencing investor sentiment and stock valuation in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma plc appointed Kenneth Sun as Senior VP and Head of Asia, effective May 2026. He will oversee the company's royalty operations in Asia from Hong Kong.
Why It Matters
Kenneth Sun's appointment as SVP for Asia could enhance Royalty Pharma's market presence and growth potential in the region, impacting revenue and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma plc will provide $250 million to Zymeworks Inc. via a non-recourse royalty-backed note, with repayments sourced from 30% of worldwide royalties on Ziihera® from Jazz and BeOne.
Why It Matters
The $250 million funding agreement indicates confidence in Zymeworks' pipeline, potentially boosting its valuation and impacting stock performance positively for both companies involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma plc (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026, at 1:10 p.m. ET.
Why It Matters
Royalty Pharma's participation in a major healthcare conference may signal its strategic direction and provide insights into its pipeline, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma reported strong FY25 results with double-digit growth in Royalty and Portfolio Receipts. They expanded with $2.6B in new royalties, $1.2B in share buybacks, and a 7% dividend increase. Synthetic royalties are now a key growth driver.
Why It Matters
Royalty Pharma's strong FY25 results and growth in synthetic royalties signal robust financial health, attractive returns through buybacks, and increased dividends, enhancing investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Royalty Pharma reported Q4 receipts of $856M, up 17%, and full-year receipts of $3.25B. They invested $2.6B in new royalties and repurchased $1.2B in shares, indicating strong capital management.
Why It Matters
Royalty Pharma's strong Q4 and full-year results, alongside significant capital deployment and share buybacks, indicate solid financial health and a commitment to shareholder value, enhancing its investment appeal.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About RPRX Stock
What is Royalty Pharma plc's (RPRX) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Royalty Pharma plc (RPRX) has a median price target of $51.00. The highest price target is $61.00 and the lowest is $46.00.
Is RPRX stock a good investment in 2026?
According to current analyst ratings, RPRX has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $45.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPRX stock?
Wall Street analysts predict RPRX stock could reach $51.00 in the next 12 months. This represents a 11.7% increase from the current price of $45.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Royalty Pharma plc's business model?
The company makes money by acquiring royalties that provide it with a share of the sales from approved therapies and developmental products. By partnering with various innovators across the life sciences sector, it generates revenue through these royalty payments, while also offering non-dilutive funding solutions to support clinical trials and product launches.
What is the highest forecasted price for RPRX Royalty Pharma plc?
The highest price target for RPRX is $61.00 from at , which represents a 33.6% increase from the current price of $45.65.
What is the lowest forecasted price for RPRX Royalty Pharma plc?
The lowest price target for RPRX is $46.00 from Matthew Harrison at Morgan Stanley, which represents a 0.8% increase from the current price of $45.65.
What is the overall RPRX consensus from analysts for Royalty Pharma plc?
The overall analyst consensus for RPRX is bullish. Out of 11 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $51.00.
How accurate are RPRX stock price projections?
Stock price projections, including those for Royalty Pharma plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 4:03 PM UTC